Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-cohort, dose-escalation study of XL888 with a fixed dose of vemurafenib. New
dose escalation or de-escalation cohorts will be assigned by the Principal Investigator (PI)
with discussion with appropriate co-investigators once safety and tolerability is known for a
given cohort in accordance to dose escalation rules. Participants will be defined to be
enrolled within a cohort upon receipt of first dose of XL888/vemurafenib.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute